A molecular test from Becton Dickinson that detects viruses that cause Covid-19 as well as influenza and produces result in 2-3 hours was given emergency use authorization by the U.S. health regulator.
South Korea’s Celltrion Inc. received emergency use authorization (EUA) from the U.S. Food and Drug Administration for the rapid Covid-19 testing kit Sampinute, which boosted shares of the company and its affiliates.
U.S. manufacturers are sharply increasing production of cheap, fast – but less accurate – Covid-19 tests, aiming for 100 million per month by year-end 2020 that will enable schools and workplaces to significantly expand testing.
A Covid-19 vaccine could be broadly rolled out in the United States by the middle of 2021 or a little later, the head of the federal government’s disease control agency said.
More U.S. colleges were grappling with high numbers of students testing positive for the coronavirus just days into the start of the fall semester after some universities rolled back their campus reopening plans in recent weeks.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
The U.S. Food and Drug Administration said the regulatory agency would require antibody tests for the new coronavirus to undergo an agency review, reversing an earlier policy that had allowed fraudulent products to be marketed.
United Nations leaders called for a global effort to develop and distribute to all at affordable prices vaccines, treatments and testing kits against COVID-19.
Merck & Co. Inc., Pfizer Inc., and Eli Lilly and Company announced medical service volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay.
U.S. Vice President Mike Pence promised that Americans would have access in the days ahead to more than 2,000 laboratories capable of processing coronavirus tests, and a leading expert said the country would launch a new phase of testing for the fast-spreading disease.